Telix Pharmaceuticals Limited

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP

Q8973A105
SEDOL

BF7M092
CIK

N/A

telixpharma.com
LEI:
FIGI: BBG00HZHXWM5
TLX

Telix Pharmaceuticals Limited
GICS: - · Sektor: Pharmaceuticals, Biotechnology & Life Sciences · Sub-Sektor: -
AI
PROFILER
NAME
Telix Pharmaceuticals Limited
ISIN
AU000000TLX2
TICKER
TLX
MIC
XASX
REUTERS
TLX.AX
BLOOMBERG
TLX AU
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants

Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von PR-Newswire bereitgestellt.

Mi., 12.02.2025       Telix Pharmaceuticals
AU000000TLX2

MELBOURNE, Australia, Feb. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).

Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging[2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[3] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[4].

Mi., 12.02.2025       Telix Pharmaceuticals
AU000000TLX2

MELBOURNE, Australia, Feb. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).

Do., 30.01.2025       Telix Pharmaceuticals
AU000000TLX2

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities[1].

Mo., 27.01.2025       Telix Pharmaceuticals
AU000000TLX2

MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic radiopharmaceuticals. 

The acquisition immediately enhances Telix's presence in the United States (U.S.), with a network of over 30 radiopharmacies[3] dispensing radiopharmaceuticals manufactured by Telix and other companies, while bringing a team of highly-skilled and multi-disciplinary radiopharmaceutical professionals into the Company.  

Do., 23.01.2025       Telix Pharmaceuticals
AU000000TLX2

INGLEWOOD, Kalifornien, 23. Januar 2025 /PRNewswire/ -- ImaginAb, Inc., gibt bekannt, dass es eine Vereinbarung über den Verkauf einer Pipeline von therapeutischen Kandidaten der nächsten Generation, einer firmeneigenen neuartigen Technologieplattform für Biologika und einer Forschungseinrichtung für Protein-Engineering und -Entdeckung an Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL) getroffen hat.

Nach Abschluss der Transaktion wird sich ImaginAb Inc. auf die Entwicklung seines führenden Bildgebungskandidaten CD8 ImmunoPET konzentrieren, der sich derzeit in klinischen Studien der Phase 2 befindet und von zahlreichen pharmazeutischen und biotechnologischen Unternehmen für die Bildgebung in klinischen Studien zur Immuntherapie, vor allem in der Onkologie, lizenziert wurde. Darüber hinaus wird ImaginAb weiterhin als Partner an der Weiterentwicklung des entscheidenden Prostatakrebs-Imaging-Mittels mitwirken, das derzeit in klinischen Phase-2-Studien und als chirurgisches Resektionsmittel geprüft wird.  

Mi., 22.01.2025       Telix Pharmaceuticals
AU000000TLX2

INGLEWOOD, Calif., Jan. 22, 2025 /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL).

Following the closing of this transaction, ImaginAb Inc., will focus on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within immunotherapy clinical trials, primarily in oncology. In addition, ImaginAb will continue to partner in advancing the pivotal prostate cancer imaging agent, which is currently being evaluated in Phase 2 clinical trials and as a surgical resection tool.  

Mi., 22.01.2025       Telix Pharmaceuticals
AU000000TLX2

INGLEWOOD, Calif., Jan. 22, 2025 /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TXL).

Following the closing of this transaction, ImaginAb Inc., will focus on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within immunotherapy clinical trials, primarily in oncology. In addition, ImaginAb will continue to partner in advancing the pivotal prostate cancer imaging agent, which is currently being evaluated in Phase 2 clinical trials and as a surgical resection tool.  

Do., 16.01.2025       Telix Pharmaceuticals
AU000000TLX2

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).

This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM[2] as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)[3] agree that Illuccix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country[4].

Do., 16.01.2025       Telix Pharmaceuticals
AU000000TLX2

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).

Mo., 13.01.2025       Telix Pharmaceuticals
AU000000TLX2

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.). 

The presentation will take place this Wednesday, 15 January at 2:15 pm PST (5:15 pm EST / 9:15 am AEDT, 16 January). 

We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S